References
Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487.
Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142: 155–158.
Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125:1363–1366.
Fung AE, Rosenfeld PJ, Reichel E The international intravitreal bevacizumab safety survey: using the interest to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344–1349.
Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807–4813.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mizote, M., Baba, T., Hirooka, K. et al. Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma. Jpn J Ophthalmol 54, 242–244 (2010). https://doi.org/10.1007/s10384-009-0788-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-009-0788-y